

T NO 69 Technical Evaluation Report

S.No	Item code	Item Name	Firm Remarks	Item Remarks
1	Drreddyslaboratorieslimited		Firm Remarks : May be Considered	May be Considered
	3456.03	Favipiravir Tablets 200mg		May be Considered
	3456.02	Remdesivir 100mg Injection		May be Considered
2	Glenmark Pharmaceuticals Ltd		Firm Remarks : May be Considered	May be Considered
	3456.03	Favipiravir Tablets 200mg		May be Considered
3	Hetero Healthcare Limited		Firm Remarks : May be considered after submission of valid drug license/product permission in the name of M/s Hetro Healthcare Limited was not submitted	May not be considered
	3456.03	Favipiravir Tablets 200mg	May be considered after submission of valid drug license	May not be considered
	3456.02	Remdesivir 100mg Injection	May be considered after submission of valid drug license	May not be considered
4	Msn Laboratories Ltd		Firm Remarks : May be Considered	May be Considered
	3456.03	Favipiravir Tablets 200mg		May be Considered
5	Mylan Laboratories Limited		Firm Remarks : May be Considered	May be Considered
	3456.02	Remdesivir 100mg Injection		May be Considered
6	Pure And Cure Healthcare Private Limited		Firm Remarks : May be Considered	May be Considered
	3456.03	Favipiravir Tablets 200mg		May be Considered
7	Sun Pharma Laboratories Limited		Firm Remarks : May be consider after submission of valid GMP/WHO-GMP Certificate,Valid product approval license,valid imported and NCC Certificate, Authorization letter of nominating responsible person, Annexure-II, Turn over certificate from CA and Details of shelf life, Manufacturing Capacity & Batch sizes wih Manufacturing Address.	May not be considered
	3456.03	Favipiravir Tablets 200mg	May be considered after submission of valid drug license	May not be considered

Note: All the bidders are here by requested to verify the Provisional Technical Evaluation Report and submit their supporting documents on or before 11.59 A.M on 05.09.2020 to the email id: tenders.apmsidc@gmail.com with Subject : Reply to T No 69 (Covid Medicines) Preliminary TEC Report.